Sun Pharmaceutical Industries Ltd said it was allowed to launch a generic version of Novartis’ leukemia drug Gleevec in the United States on Feb. 1, 2016, under a settlement agreement between the two companies.

The other terms of the agreement are confidential, Sun Pharma said in a statement on Thursday.

Sun Pharma’s subsidiary holds a tentative approval from the U.S Food and Drug Administration for a generic version of Gleevec. As per IMS data, Gleevec had annual sales of about $2 billion in the United States, Sun said.